Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.18
ACET's Cash-to-Debt is ranked lower than
88% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. ACET: 0.18 )
Ranked among companies with meaningful Cash-to-Debt only.
ACET' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 4.89 Max: 83.22
Current: 0.18
0.18
83.22
Equity-to-Asset 0.38
ACET's Equity-to-Asset is ranked lower than
79% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. ACET: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
ACET' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38  Med: 0.66 Max: 0.77
Current: 0.38
0.38
0.77
Interest Coverage 4.15
ACET's Interest Coverage is ranked lower than
84% of the 646 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. ACET: 4.15 )
Ranked among companies with meaningful Interest Coverage only.
ACET' s Interest Coverage Range Over the Past 10 Years
Min: 4.15  Med: 18.65 Max: 147.43
Current: 4.15
4.15
147.43
Piotroski F-Score: 3
Altman Z-Score: 1.63
Beneish M-Score: -1.99
WACC vs ROIC
9.77%
5.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 7.05
ACET's Operating Margin % is ranked lower than
54% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.38 vs. ACET: 7.05 )
Ranked among companies with meaningful Operating Margin % only.
ACET' s Operating Margin % Range Over the Past 10 Years
Min: 2.72  Med: 5.83 Max: 10.39
Current: 7.05
2.72
10.39
Net Margin % 3.84
ACET's Net Margin % is ranked lower than
60% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. ACET: 3.84 )
Ranked among companies with meaningful Net Margin % only.
ACET' s Net Margin % Range Over the Past 10 Years
Min: 1.9  Med: 3.79 Max: 6.22
Current: 3.84
1.9
6.22
ROE % 6.59
ACET's ROE % is ranked lower than
54% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.12 vs. ACET: 6.59 )
Ranked among companies with meaningful ROE % only.
ACET' s ROE % Range Over the Past 10 Years
Min: 4.68  Med: 10.25 Max: 13.73
Current: 6.59
4.68
13.73
ROA % 3.29
ACET's ROA % is ranked lower than
54% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. ACET: 3.29 )
Ranked among companies with meaningful ROA % only.
ACET' s ROA % Range Over the Past 10 Years
Min: 3.01  Med: 6.16 Max: 7.33
Current: 3.29
3.01
7.33
ROC (Joel Greenblatt) % 20.94
ACET's ROC (Joel Greenblatt) % is ranked higher than
60% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.08 vs. ACET: 20.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACET' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.2  Med: 25.97 Max: 38.21
Current: 20.94
12.2
38.21
3-Year Revenue Growth Rate 1.20
ACET's 3-Year Revenue Growth Rate is ranked lower than
64% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. ACET: 1.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACET' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.9  Med: 4.2 Max: 14.9
Current: 1.2
0.9
14.9
3-Year EBITDA Growth Rate 16.10
ACET's 3-Year EBITDA Growth Rate is ranked higher than
62% of the 536 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. ACET: 16.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACET' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -11.3  Med: 7.6 Max: 44.7
Current: 16.1
-11.3
44.7
3-Year EPS without NRI Growth Rate 13.40
ACET's 3-Year EPS without NRI Growth Rate is ranked higher than
61% of the 506 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. ACET: 13.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACET' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -17.5  Med: 7.9 Max: 46.1
Current: 13.4
-17.5
46.1
GuruFocus has detected 4 Warning Signs with Aceto Corp $ACET.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACET's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ACET Guru Trades in Q1 2016

Chuck Royce 423,190 sh (+37.49%)
Ken Fisher 185,471 sh (+0.05%)
Paul Tudor Jones 10,600 sh (-20.30%)
Jim Simons 83,300 sh (-72.04%)
» More
Q2 2016

ACET Guru Trades in Q2 2016

Keeley Asset Management Corp 47,700 sh (New)
Chuck Royce 1,215,573 sh (+187.24%)
Paul Tudor Jones Sold Out
Ken Fisher 167,853 sh (-9.50%)
Jim Simons 20,100 sh (-75.87%)
» More
Q3 2016

ACET Guru Trades in Q3 2016

Chuck Royce 2,522,555 sh (+107.52%)
Keeley Asset Management Corp 71,750 sh (+50.42%)
Jim Simons Sold Out
Ken Fisher 122,091 sh (-27.26%)
» More
Q4 2016

ACET Guru Trades in Q4 2016

Paul Tudor Jones 15,200 sh (New)
Keeley Asset Management Corp 71,050 sh (-0.98%)
Chuck Royce 1,743,186 sh (-30.90%)
Ken Fisher 70,105 sh (-42.58%)
» More
» Details

Insider Trades

Latest Guru Trades with ACET

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:LBIO, OTCPK:ACBFF, NAS:SCLN, NAS:SCMP, OTCPK:ARSUF, OTCPK:OWCP, NAS:RIGL, NAS:ARLZ, NAS:AMPH, NAS:HRTX, NAS:SMMT, OTCPK:SENZ, NAS:DRRX, OTCPK:ORXOY, OTCPK:ELTP, NAS:MSLI, NAS:CPIX, NAS:CPRX, OTCPK:CPHRF, NAS:BPTH » details
Traded in other countries:AZJ.Germany,
Aceto Corp is engaged in the marketing, sells and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, and specialty performance chemicals.

Aceto Corp is engaged in the marketing, sales and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals. Its operations are organized into three segments - Human Health, Pharmaceutical Ingredients and Performance Chemicals. The Human Health segment supply's raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations. This segment markets and distributes its generic prescription and over the counter pharmaceutical products to wholesalers; chain drug stores; distributors; mass market merchandisers; and others. The Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates to various generic drug companies. The Performance Chemicals segment provides specialty chemicals, such as antioxidants, photo initiators, catalysts, curatives, brighteners, and adhesion promoters, which make plastics, surface coatings, textiles, fuels, and lubricants; diazos and couplers used in microfilms and blueprints, as well as in the photo tooling of printed circuit boards; and organic intermediates and colorants. Its raw materials are also used in electronic parts and binders. This segment also offers agricultural protection products comprising herbicides, fungicides, and insecticides, which control weed growth and the spread of insects and microorganisms; and sprout inhibitor for potatoes. The Company serves various companies, including small trading and fortune 500 companies in the industrial chemical, agricultural, and human health and pharmaceutical market.

Ratios

vs
industry
vs
history
PE Ratio 21.68
ACET's PE Ratio is ranked higher than
64% of the 453 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.06 vs. ACET: 21.68 )
Ranked among companies with meaningful PE Ratio only.
ACET' s PE Ratio Range Over the Past 10 Years
Min: 8.5  Med: 19.92 Max: 91.83
Current: 21.68
8.5
91.83
Forward PE Ratio 9.97
ACET's Forward PE Ratio is ranked higher than
84% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.82 vs. ACET: 9.97 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.68
ACET's PE Ratio without NRI is ranked higher than
65% of the 447 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.19 vs. ACET: 21.68 )
Ranked among companies with meaningful PE Ratio without NRI only.
ACET' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.5  Med: 19.85 Max: 91.83
Current: 21.68
8.5
91.83
Price-to-Owner-Earnings 22.62
ACET's Price-to-Owner-Earnings is ranked higher than
66% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.27 vs. ACET: 22.62 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ACET' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.52  Med: 23.07 Max: 178.65
Current: 22.62
7.52
178.65
PB Ratio 1.17
ACET's PB Ratio is ranked higher than
84% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. ACET: 1.17 )
Ranked among companies with meaningful PB Ratio only.
ACET' s PB Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.56 Max: 3.37
Current: 1.17
0.83
3.37
PS Ratio 0.84
ACET's PS Ratio is ranked higher than
85% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. ACET: 0.84 )
Ranked among companies with meaningful PS Ratio only.
ACET' s PS Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.61 Max: 1.62
Current: 0.84
0.31
1.62
Price-to-Free-Cash-Flow 15.08
ACET's Price-to-Free-Cash-Flow is ranked higher than
68% of the 185 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.92 vs. ACET: 15.08 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACET' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.68  Med: 21.57 Max: 571.58
Current: 15.08
7.68
571.58
Price-to-Operating-Cash-Flow 12.86
ACET's Price-to-Operating-Cash-Flow is ranked higher than
62% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.34 vs. ACET: 12.86 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACET' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.09  Med: 17.22 Max: 223.33
Current: 12.86
6.09
223.33
EV-to-EBIT 18.98
ACET's EV-to-EBIT is ranked higher than
52% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.61 vs. ACET: 18.98 )
Ranked among companies with meaningful EV-to-EBIT only.
ACET' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.2  Med: 11.2 Max: 45.7
Current: 18.98
4.2
45.7
EV-to-EBITDA 14.32
ACET's EV-to-EBITDA is ranked higher than
57% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.32 vs. ACET: 14.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACET' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 9.45 Max: 22.2
Current: 14.32
4
22.2
PEG Ratio 0.97
ACET's PEG Ratio is ranked higher than
74% of the 266 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. ACET: 0.97 )
Ranked among companies with meaningful PEG Ratio only.
ACET' s PEG Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.17 Max: 18.99
Current: 0.97
0.35
18.99
Shiller PE Ratio 22.11
ACET's Shiller PE Ratio is ranked higher than
79% of the 157 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.81 vs. ACET: 22.11 )
Ranked among companies with meaningful Shiller PE Ratio only.
ACET' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.39  Med: 21.4 Max: 46.78
Current: 22.11
11.39
46.78
Current Ratio 2.21
ACET's Current Ratio is ranked lower than
51% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. ACET: 2.21 )
Ranked among companies with meaningful Current Ratio only.
ACET' s Current Ratio Range Over the Past 10 Years
Min: 2.12  Med: 3.01 Max: 4
Current: 2.21
2.12
4
Quick Ratio 1.52
ACET's Quick Ratio is ranked lower than
57% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. ACET: 1.52 )
Ranked among companies with meaningful Quick Ratio only.
ACET' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.88 Max: 2.71
Current: 1.52
1.21
2.71
Days Inventory 97.77
ACET's Days Inventory is ranked higher than
59% of the 567 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.74 vs. ACET: 97.77 )
Ranked among companies with meaningful Days Inventory only.
ACET' s Days Inventory Range Over the Past 10 Years
Min: 76.06  Med: 81.97 Max: 97.77
Current: 97.77
76.06
97.77
Days Sales Outstanding 149.76
ACET's Days Sales Outstanding is ranked lower than
86% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. ACET: 149.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACET' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.39  Med: 74.13 Max: 149.76
Current: 149.76
61.39
149.76
Days Payable 79.49
ACET's Days Payable is ranked higher than
57% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. ACET: 79.49 )
Ranked among companies with meaningful Days Payable only.
ACET' s Days Payable Range Over the Past 10 Years
Min: 34.34  Med: 45.41 Max: 79.49
Current: 79.49
34.34
79.49

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.62
ACET's Dividend Yield % is ranked higher than
50% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. ACET: 1.62 )
Ranked among companies with meaningful Dividend Yield % only.
ACET' s Dividend Yield % Range Over the Past 10 Years
Min: 0.79  Med: 2.1 Max: 4.01
Current: 1.62
0.79
4.01
Dividend Payout Ratio 0.35
ACET's Dividend Payout Ratio is ranked higher than
53% of the 378 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.36 vs. ACET: 0.35 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ACET' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.34 Max: 0.77
Current: 0.35
0.2
0.77
3-Year Dividend Growth Rate 2.90
ACET's 3-Year Dividend Growth Rate is ranked lower than
64% of the 270 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. ACET: 2.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ACET' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -1.5  Med: 6.3 Max: 22.6
Current: 2.9
-1.5
22.6
Forward Dividend Yield % 1.69
ACET's Forward Dividend Yield % is ranked higher than
52% of the 612 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. ACET: 1.69 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.02
ACET's 5-Year Yield-on-Cost % is ranked lower than
52% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. ACET: 2.02 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ACET' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.98  Med: 2.62 Max: 5
Current: 2.02
0.98
5
3-Year Average Share Buyback Ratio -2.10
ACET's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. ACET: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACET' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.4  Med: -2.1 Max: 4.7
Current: -2.1
-4.4
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.93
ACET's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
86% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.61 vs. ACET: 0.93 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACET' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.48  Med: 1.04 Max: 2.73
Current: 0.93
0.48
2.73
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.15
ACET's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
65% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. ACET: 1.15 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.37
ACET's Price-to-Median-PS-Value is ranked lower than
60% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.22 vs. ACET: 1.37 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACET' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.39  Med: 0.91 Max: 2.4
Current: 1.37
0.39
2.4
Price-to-Peter-Lynch-Fair-Value 1.39
ACET's Price-to-Peter-Lynch-Fair-Value is ranked higher than
55% of the 163 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. ACET: 1.39 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ACET' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.4  Med: 1.2 Max: 6.02
Current: 1.39
0.4
6.02
Earnings Yield (Greenblatt) % 5.30
ACET's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 611 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. ACET: 5.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACET' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 8.9 Max: 23.6
Current: 5.3
2.2
23.6
Forward Rate of Return (Yacktman) % 19.78
ACET's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 353 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.48 vs. ACET: 19.78 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACET' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.4  Med: 12.3 Max: 48.8
Current: 19.78
-1.4
48.8

More Statistics

Revenue (TTM) (Mil) $546.9
EPS (TTM) $ 0.71
Beta1.18
Short Percentage of Float9.79%
52-Week Range $14.67 - 25.98
Shares Outstanding (Mil)30.11

Analyst Estimate

Jun17 Jun18
Revenue (Mil $) 655 756
EPS ($) 1.54 1.88
EPS without NRI ($) 1.54 1.88
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ACET

Headlines

Articles On GuruFocus.com
9 Cheap High-Yield Stocks Feb 23 2017 
5 Biggest Dividend Hikes Of The Past Week Aug 31 2013 
Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 
Aceto Corp. Reports Operating Results (10-Q) Feb 04 2011 
Aceto Corp. Reports Operating Results (10-Q) Nov 05 2010 
Aceto Corp. Reports Operating Results (10-Q) May 07 2010 
Aceto Corp. Reports Operating Results (10-Q) Feb 05 2010 
Aceto Corp. Reports Operating Results (10-Q) Nov 06 2009 
Aceto Corp. Reports Operating Results (10-Q) May 08 2009 
Aceto Corp. Reports Operating Results (10-Q) Feb 06 2009 

More From Other Websites
Top Ranked Value Stocks to Buy for February 27th Feb 27 2017
Top Ranked Value Stocks to Buy for February 24th Feb 24 2017
Top Ranked Value Stocks to Buy for February 22nd Feb 22 2017
Top Ranked Value Stocks to Buy for February 21st Feb 21 2017
ACETO CORP Files SEC form 8-K/A, Financial Statements and Exhibits Feb 17 2017
Top Ranked Value Stocks to Buy for February 16th Feb 16 2017
ACETO to Present at the 2017 RBC Capital Markets Global Healthcare Conference Feb 15 2017
Verdezyne Launches New Corrosion Inhibitor Feb 15 2017
ETFs with exposure to Aceto Corp. : February 14, 2017 Feb 14 2017
Top Ranked Value Stocks to Buy for February 14th Feb 14 2017
Aceto (ACET) is Oversold: Can It Recover? Feb 10 2017
ACETO CORP Financials Feb 09 2017
Top Ranked Value Stocks to Buy for February 9th Feb 09 2017
Aceto Corp. :ACET-US: Earnings Analysis: Q2, 2017 By the Numbers : February 7, 2017 Feb 07 2017
Top Ranked Value Stocks to Buy for February 7th Feb 07 2017
Top Ranked Value Stocks to Buy for February 6th Feb 06 2017
ACETO CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 03 2017
Top Ranked Value Stocks to Buy for February 3rd Feb 03 2017
Aceto reports 2Q loss Feb 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)